Alert: Rabeprazole sodium 10mg/20mg gastro-resistant tablets

Bristol Laboratories Limited has advised that the Patient Information Leaflet (PIL) in three batches each of rabeprazole sodium 10mg and 20mg gastro-resistant tablets do not contain the most up to date safety information. Sections 2-4 of the PILs are affected.

View the affected batches online

Affected batches are not being recalled. Healthcare professionals should provide a copy of the updated PIL available via the following links:

Rabeprazole sodium 10mg gastro-resistant tablets

Rabeprazole sodium 20mg gastro-resistant Tablets

Patients should continue to take medicines from these batches.

MHRA alert

Latest news

England & Wales: initial August concession price update

The Department of Health and Social Care has published an initial update to the initial list of August concessions. In this update, there are 48 new prices DDA members can download a fully updated spreadsheet of the Aug

New CD guidance for limited companies

The DDA and the Healthcare Distribution Association (HDA) has published joint guidance on the supply of Controlled Drugs to GP practices constituted as a limited company. In summary, two core regulatory requirements apply: Care regulator registra

Dispensing cross subsidy highlighted in rural GP funding critique

The role of dispensing income as a cross subsidy for rural NHS GP funding has been highlighted in a new paper by a think-tank. Noting the funding challenges of delivering NHS GP services in rural areas, General practice funding in England publ

Alert: Rabeprazole sodium 10mg/20mg gastro-resistant tablets

Latest news

England & Wales: initial August concession price update

New CD guidance for limited companies

Dispensing cross subsidy highlighted in rural GP funding critique

View all news

Gold Supporters

Follow us

Dispensing Doctors' Association

DDA Best Practice Group

Dispensing Doctors' Association